In 2026, Adjuvax will collaborate with UAB and Auburn University on a project to develop an antibacterial poultry vaccine.
In 2026, Adjuvax received a Phase II Innovate Alabama Supplemental Grant to evaluate our mucosal adjuvant for an animal vaccine.
Adjuvax attended the 2026 World Vaccine Congress in Washington DC as a startup biotech company.
Adjuvax exhibited at the 2025 BIO International Convention in Boston with BIO Alabama.
Adjuvax attended the 2025 World Vaccine Congress in Washington DC as a startup biotech company.
Adjuvax received a NIH SBIR Phase II award for adjuvant discovery research and development of our saponin-based adjuvants.
In 2024, Adjuvax received a second Innovate Alabama Supplemental Grant.
In 2023, Adjuvax won the Start-Up of the Year Award from UAB Bill L. Harbert Institute for Innovation and Entrepreneurship.
In 2023, Adjuvax received an Innovate Alabama Supplemental Grant.
Read more here!
In 2022, Adjuvax secured two NIH SBIR Phase I awards for saponin adjuvant development.
Find more news, updates, and pictures on our LinkedIn!
At Adjuvax, we are dedicated to developing potent, cost-effective, structurally defined, and highly accessible saponin adjuvants with diverse activity profiles tailored to various vaccine applications.
Stay Connected: